AptarGroup (ATR) Investor Presentation - Slideshow

Financial Performance & Targets - Aptar's FY 2020 sales were $2.9 billion across various end markets [3] - Pharma segment accounted for 42% of 2020 sales, generating $1.2 billion and 68% of adjusted EBITDA, amounting to $428 million with a 35% margin [6] - Beauty + Home segment represented 44% of 2020 sales, totaling $1.3 billion, with adjusted EBITDA of $129 million and a 10% margin [6] - Food + Beverage segment contributed 14% of 2020 sales, reaching $0.4 billion, and yielded adjusted EBITDA of $72 million with an 18% margin [6] - The company targets long-term core sales growth of 4-7% and an adjusted EBITDA margin of 20-22% [44, 45] Segment Highlights & Growth - Aptar Pharma's Q1 2021 core sales growth was 0%, below the 3-year average of 10% and long-term target of 6-10% [12] - Aptar Beauty + Home experienced a -3% core sales growth in Q1 2021, also below its 3-year average of 0% and long-term target of 3-6% [15] - Aptar Food + Beverage saw a 14% core sales growth in Q1 2021, significantly exceeding its 3-year average of 1% and surpassing its long-term target of 6-10% [18] Strategic Initiatives & Sustainability - The company is committed to R&D, with approximately 3% of annual revenue allocated to it [3] - Aptar has over 1,250 patent families, demonstrating its focus on research and intellectual property [3] - The company is recognized as a Top 10 Company in Reducing Environmental Impact by JUST Capital [10]